中医药治疗原发性胆汁性胆管炎的研究进展

Research progress of integrated traditional Chinese and Western medicine in the treatment of primary bile cirrhosis

关键词:  原发性胆汁性胆管炎  中医药  研究进展

Key words:  primary biliary cirrhosis  traditional Chinese medicine  research progress

摘要:

原发性胆汁性胆管炎（PBC）是一种主要发生于肝内小叶间胆管细胞的慢性胆汁淤积性自身免疫性肝病，人群发病率为每年4~30例/万，病死人数占肝硬化病死人数的1.6%~2.0%。PBC发病机制不明确，主要认为与自身免疫有关。西医常用熊去氧胆酸（UDCA）治疗，效果欠佳。近年来，越来越多的临床试验证明中医药治疗PBC疗效确切，可显著提高临床有效率。文章主要从病因病机、中医药治疗方面综述近5年来PBC的临床治疗研究进展，同时指出了目前中医药治疗PBC研究中所存在的问题，并对未来研究进行了展望。

Abstract:

Primary bile cirrhosis (PBC) is a chronic bile stasis autoimmune liver disease that occurs mainly in intralobular bile duct cells. The incidence rate of the population is 4 to 30 cases during 10 000 people per year,and the number of deaths account for 1.6% to 2.0% of the total number of patients with liver cirrhosis. The mechanism of the PBC is not clear,which is mainly believed to be related to autoimmunity. Ursodeoxycholic acid is commonly used in western medicine,but the effect is poor. In recent years,it has been reported that traditional Chinese medicine combined with UDCA has been used in the treatment of PBC,and some curative effects have been obtained. This paper mainly reviews the research progress of clinical treatment of PBC in recent 5 years from the aspects of etiology and pathogenesis and traditional Chinese medicine treatment. At the same time,it points out the defects existing in the current research of integrated traditional Chinese in the treatment of PBC and looks forward to the future research.